Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform
Consequently, the present study showed that the novel humanized CLC bsAb JMB2005 may represent a novel therapeutic agent of great clinical potential.
Authors
- Xiaodan Cao (ORCID: https://orcid.org/0000-0001-5726-2763)
- Chunyin Gu
- Zongda Wang (ORCID: https://orcid.org/0000-0002-1662-2934)
- Haixiang Yu (ORCID: https://orcid.org/0000-0002-1100-9882)
- Huawei Zhang (ORCID: https://orcid.org/0000-0001-8589-5189)
- Peipei Liu (ORCID: https://orcid.org/0000-0001-8374-9823)
- Yukun Yang (ORCID: https://orcid.org/0009-0003-0474-2044)
- Sujun Deng
- Fangfang Jia
- Xianqing He
- Yingying Zhen
- Kedong Ouyang
Publication Details
- Journal
- Antibody Therapeutics
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1093/abt/tbae027
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00